These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 9949863)

  • 61. 5-HT receptors mediating external carotid vasoconstriction in vagosympathectomized dogs.
    Villalón CM; Centurión D; Sánchez-López A; De Vries P; Saxena P
    Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1057-67. PubMed ID: 11216445
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans.
    Géraud G; Keywood C; Senard JM
    Headache; 2003 Apr; 43(4):376-88. PubMed ID: 12656709
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Anti-migraine drug sumatriptan succinate, a 5-HT1B/1D-receptor agonist].
    Iwasawa Y; Danjo T
    Nihon Yakurigaku Zasshi; 2001 Jun; 117(6):387-93. PubMed ID: 11436516
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Novel strategies for the treatment of migraine attacks via the CGRP, serotonin, dopamine, PAC1, and NMDA receptors.
    Tajti J; Csáti A; Vécsei L
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1509-20. PubMed ID: 25253587
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Safety trial with the 5HT1B/1D agonist avitriptan (BMS-180048) in patients with migraine who have experienced pressure, tightness, and/or pain in the chest, neck, and/or throat following sumatriptan.
    Dahlöf CG; Falk L; Risenfors M; Lewis CP
    Cephalalgia; 1998 Oct; 18(8):546-51. PubMed ID: 9827246
    [TBL] [Abstract][Full Text] [Related]  

  • 66. The in vivo pharmacological profile of eletriptan (UK-116,044): a potent and novel 5-HT(1B/1D) receptor agonist.
    Gupta P; Butler P; Shepperson NB; McHarg A
    Eur J Pharmacol; 2000 Jun; 398(1):73-81. PubMed ID: 10856450
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1-yl)ethyl]indoles: potent agonists for the h5-HT1D receptor with high selectivity over the h5-HT1B receptor.
    Sternfeld F; Guiblin AR; Jelley RA; Matassa VG; Reeve AJ; Hunt PA; Beer MS; Heald A; Stanton JA; Sohal B; Watt AP; Street LJ
    J Med Chem; 1999 Feb; 42(4):677-90. PubMed ID: 10052975
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 4-Hydroxy-1-[3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyl]piperidines: selective h5-HT1D agonists for the treatment of migraine.
    Bourrain S; Neduvelil JG; Beer MS; Stanton JA; Showell GA; MacLeod AM
    Bioorg Med Chem Lett; 1999 Dec; 9(23):3369-74. PubMed ID: 10612601
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Porcine carotid vascular effects of eletriptan (UK-116,044): a new 5-HT1B/1D receptor agonist with anti-migraine activity.
    Willems E; De Vries P; Heiligers JP; Saxena PR
    Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):212-9. PubMed ID: 9750007
    [TBL] [Abstract][Full Text] [Related]  

  • 70. 5-Carboxamido-tryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129, and serotonin-5-O-carboxymethyl-glycyl -tyrosinamide block dural plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine1B receptors.
    Yu XJ; Waeber C; Castanon N; Scearce K; Hen R; Macor JE; Chauveau J; Moskowitz MA
    Mol Pharmacol; 1996 May; 49(5):761-5. PubMed ID: 8622623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.
    Millson DS; Tepper SJ; Rapoport AM
    Expert Opin Pharmacother; 2000 Mar; 1(3):391-404. PubMed ID: 11249525
    [TBL] [Abstract][Full Text] [Related]  

  • 72. BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.
    Saxena PR; De Vries P; Heiligers JP; Bax WA; Maassen VanDenBrink A; Yocca FD
    Eur J Pharmacol; 1998 Jun; 351(3):329-39. PubMed ID: 9721025
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Migraine: current therapeutic targets and future avenues.
    Arulmozhi DK; Veeranjaneyulu A; Bodhankar SL
    Curr Vasc Pharmacol; 2006 Apr; 4(2):117-28. PubMed ID: 16611154
    [TBL] [Abstract][Full Text] [Related]  

  • 74. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system.
    Limmroth V; Katsarava Z; Liedert B; Guehring H; Schmitz K; Diener HC; Michel MC
    Pain; 2001 May; 92(1-2):101-6. PubMed ID: 11323131
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vasoconstrictive properties of the 5HT1B/1D agonists: response to Dahlöf and Mathew.
    Goldstein D
    Cephalalgia; 1999 Jun; 19(5):536-7. PubMed ID: 10403072
    [No Abstract]   [Full Text] [Related]  

  • 76. Rationale for the use of 5-HT1-like agonists in the treatment of migraine.
    Feniuk W; Humphrey PP; Perren MJ; Connor HE; Whalley ET
    J Neurol; 1991; 238 Suppl 1():S57-61. PubMed ID: 1646289
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Zolmitriptan: a review of its use in migraine.
    Spencer CM; Gunasekara NS; Hills C
    Drugs; 1999 Aug; 58(2):347-74. PubMed ID: 10473025
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pharmacological synergy: the next frontier on therapeutic advancement for migraine.
    Blumenfeld A; Gennings C; Cady R
    Headache; 2012 Apr; 52(4):636-47. PubMed ID: 22221151
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Dual effect of the serotonin agonist, sumatriptan, on peripheral neurogenic inflammation.
    Pierce PA; Xie GX; Peroutka SJ; Levine JD
    Reg Anesth; 1996; 21(3):219-25. PubMed ID: 8744664
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Expression of mRNA for the serotonin 5-hydroxytryptamine1D beta receptor subtype in human and bovine cerebral arteries.
    Hamel E; Fan E; Linville D; Ting V; Villemure JG; Chia LS
    Mol Pharmacol; 1993 Aug; 44(2):242-6. PubMed ID: 8394988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.